---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-022559"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:57:27.493722+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF

## Summary
- RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.
- BVF exchanged 1,750,000 shares for a warrant to acquire 1,750,000 shares.
- Post-exchange shares outstanding as of Jan 23, 2026: 51,007,874; warrants exercisable for 16,935,665 total shares.
- Warrants have $0.0001 exercise price, no expiration, and 4.99%/9.99% beneficial ownership blocker.
- Issued in reliance on Section 3(a)(9) exemption from registration.

## SEC filing metadata
- accession: 0001193125-26-022559
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/0001193125-26-022559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/fdmt-20260122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-022559
- JSON: https://secwatch.observer/filing/0001193125-26-022559.json
- Plain text: https://secwatch.observer/filing/0001193125-26-022559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.